Helix BioPharma (HBP)
Helix BioPharma Long Term Debt: 0.00
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
HBP Long Term Debt Rankings
| Overall | 99th percentile | 1 of 4658 |
| Sector | 99th percentile | 1 of 525 in Healthcare |
| Industry | 98th percentile | 1 of 78 in Medical Appliances & Equipment |
HBP Long Term Debt Range, Past 5 Years
| Minimum | 0.00 | Jul 2007 |
| Maximum | 0.00 | Jul 2007 |
| Average | 0.00 |
About Long Term Debt
Long-term debts are financial obligations and loans lasting longer than one year. A company must report long-term debt on its balance sheet with its date of maturity and interest rate.
Bonds and debt obligations with maturities greater than one year are examples of long-term debt. Other types of securities, including short-term notes and commercial papers usually are not long-term debt because their maturities typically are shorter than one year.
Learn More
You may also be interested in these HBP related companies
HBP News
Helix BioPharma (HBP) Announces Court Approval of Shareholder Settlement
May 07, 5:48PM Street Insider
May 07, 5:48PM Street Insider
Helix BioPharma Corp. Updates Shareholders on Court Approval of Settlement
May 07, 5:41PM Marketwire
May 07, 5:41PM Marketwire
Helix BioPharma Corp. Reconstituted Board of Directors Provides Update to Shareholders
Apr 05, 5:50PM Marketwire
Apr 05, 5:50PM Marketwire
Helix BioPharma Corp. Updates Shareholders on Results From Annual General Meeting
Jan 30, 9:05PM Marketwire
Jan 30, 9:05PM Marketwire
Helix BioPharma (HBP) Reports Troubling Findings Following Shareholder Investigation
Jan 26, 6:50AM Street Insider
Jan 26, 6:50AM Street Insider
Special Committee of Helix BioPharma Corp. Provides Update to Shareholders
Jan 25, 8:08PM Marketwire
Jan 25, 8:08PM Marketwire
Helix BioPharma (HBP) Reports Institutional Shareholder Services Encourages Shareholders Vote for Management Nominees
Jan 23, 4:55PM Street Insider
Jan 23, 4:55PM Street Insider
Helix BioPharma Corp. Proposes New Board Slate for January 30, 2012 Annual General Meeting
Jan 07, 12:11AM Marketwire
Jan 07, 12:11AM Marketwire
Michael Burry Write ups from 2000 http://stks.co/1PaJ $CR $HBP $SPY $VCLK
about 175 days ago by valuewalk
about 175 days ago by valuewalk
The Special Committee of Helix BioPharma Corp. Provides Update to Shareholders
Dec 06, 11:12AM Marketwire
Dec 06, 11:12AM Marketwire
FDA Lifts Clinical Hold on Helix BioPharma (HBP) Topical Interferon Alpha-2b, Phase II/III IND
Nov 11, 6:53AM Street Insider
Nov 11, 6:53AM Street Insider
Helix BioPharma terminates agreement with ACM Alpha Consulting Management
Oct 21, 4:51AM FlyOnTheWall
Oct 21, 4:51AM FlyOnTheWall
Helix BioPharma Corp. Terminates Agreement With ACM Alpha Consulting Management Est.
Oct 20, 8:51PM Marketwire
Oct 20, 8:51PM Marketwire
Helix BioPharma Corp. Receives Shareholder Requisition to Hold Meeting to Elect Directors
Oct 18, 5:19PM Marketwire
Oct 18, 5:19PM Marketwire
Helix BioPharma (HBP) Files IND Response for Topical Interferon Phase II/III
Oct 13, 6:38AM Street Insider
Oct 13, 6:38AM Street Insider
Helix BioPharma receives approval for European Phase I/II clinical study
Jul 25, 6:41AM FlyOnTheWall
Jul 25, 6:41AM FlyOnTheWall
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HBP | 1.52 | -0.08 | -5.00% | 102.17M |
| HBOS | 12.26 | -0.09 | -0.73% | |
| HBAN | 6.64 | +0.18 | +2.79% | 5.593B |
| HAYN | 54.43 | -0.18 | -0.33% | 671.16M |
| HAV | 8.85 | +0.00 | +0.00% | |
| HAUP | 1.19 | +0.01 | +1.28% | 11.89M |
| HAST | 2.12 | +0.00 | +0.00% | 17.77M |
| HAS | 35.53 | +0.62 | +1.78% | 4.491B |
| HARL | 17.99 | +0.10 | +0.56% | 66.74M |
| HAR | 41.61 | +1.02 | +2.51% | 2.849B |
